Overview

The purpose of this study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants with Early Alzheimer's Disease.

Eligibility

Inclusion Criteria

• Mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or mild AD dementia consistent with the National Institute on Aging and the Alzheimer's Association (NIA-AA) core clinical criteria.
• Global Clinical Dementia Rating (CDR) score of 0.5 to 1.0 and a CDR-Memory Box score of 0.5 and greater at screening and Baseline.
• Evidence of AD pathology.
• Objective impairment in episodic memory as indicated by at least 1 standard deviation below age-adjusted mean in the Wechsler Memory Scale IV-Logical Memory Subtest II (WMS-IV LM II).
• Mini Mental Status Examination (MMSE) score ≥ 20 to 28 (inclusive).

Exclusion Criteria

• Any evidence of a condition that may affect cognition other than AD.
• Contraindications to PET imaging.
• Inability to tolerate or contraindication to magnetic resonance imaging.
• Any serious medical condition that could, in the opinion of the investigator, affect the participant's safety or interfere with study assessments.
• Geriatric Depression Scale (GDS) score greater than or equal to 8 at screening.
• Other protocol-defined Inclusion/Exclusion criteria apply.